Skip to main content
Top
Published in: Respiratory Research 1/2011

Open Access 01-12-2011 | Letter to the Editor

E pluribus plurima: Multidimensional indices and clinical phenotypes in COPD

Authors: Andrea Rossi, Erika Zanardi

Published in: Respiratory Research | Issue 1/2011

Login to get access

Excerpt

Chronic Obstructive Pulmonary Disease (COPD) is a disorder of the respiratory system characterized by progressive and only partially reversible airflow obstruction, due to a varying combination of large (bronchitis) and small airways (small airway disease) damage, and lung parenchymal and vascular destruction [1]. We prefer the term obstruction to airflow limitation because the latter is a physiologic event which occurs also in normals at high levels of ventilation, for example during exercise. The correct definition should be "excessive airflow limitation" to indicate that the reduction in airflow occurs at lower level of ventilation than in normal condition. The diagnostic procedure for COPD starts from the recognition of risk factors (cigarette smoking "in primis", but also outdoor and indoor air pollution [2]) and the presence of symptoms such as chronic cough and phlegm and reduced exercise tolerance. The lifestyle is important for the reveal of symptoms: dyspnea occurs later in a sedentary person than in an active individual. …
Literature
2.
go back to reference Salvi SS, Barnes PJ: Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009, 374: 733-743. 10.1016/S0140-6736(09)61303-9.CrossRefPubMed Salvi SS, Barnes PJ: Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009, 374: 733-743. 10.1016/S0140-6736(09)61303-9.CrossRefPubMed
3.
go back to reference GOLD: Global Initiative for Chronic Obstruction Lung Disease. Global Strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2010, [http://www.goldcopd.com] GOLD: Global Initiative for Chronic Obstruction Lung Disease. Global Strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2010, [http://​www.​goldcopd.​com]
4.
go back to reference Celli BR, MacNee W: Standard for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004, 23: 932-946. 10.1183/09031936.04.00014304.CrossRefPubMed Celli BR, MacNee W: Standard for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004, 23: 932-946. 10.1183/09031936.04.00014304.CrossRefPubMed
5.
go back to reference Vestbo J, Rodriguez-Rosin R: GOLD and the fixed ratio. Eur Respir J. 2011, 38: 481-2. 10.1183/09031936.00042411.CrossRefPubMed Vestbo J, Rodriguez-Rosin R: GOLD and the fixed ratio. Eur Respir J. 2011, 38: 481-2. 10.1183/09031936.00042411.CrossRefPubMed
6.
go back to reference O'Donnell DE, Aron S, Bourbeau J, Hernandez P, Marciniuk D, Balter M, Ford G, Gervais A, Goldstein R, Hodder R, Maltais F, Road J: Canadian Thoracic Society Recommendations for Management of Chronic Obstructive Pulmonary Disease - 2003. Can Respir J. 2003, 10 (Suppl A): 11A-33A.CrossRefPubMed O'Donnell DE, Aron S, Bourbeau J, Hernandez P, Marciniuk D, Balter M, Ford G, Gervais A, Goldstein R, Hodder R, Maltais F, Road J: Canadian Thoracic Society Recommendations for Management of Chronic Obstructive Pulmonary Disease - 2003. Can Respir J. 2003, 10 (Suppl A): 11A-33A.CrossRefPubMed
7.
go back to reference Quanjer PH, Enright PL, Miller MR, Stocks J, Ruppel G, Swanney MP, Crapo RO, Pedersen OF, Falaschetti E, Schouten JP, Jensen RL: The need to change the method for defining mild airway obstruction. Eur Respir J. 2011, 37: 720-722. 10.1183/09031936.00135110.CrossRefPubMed Quanjer PH, Enright PL, Miller MR, Stocks J, Ruppel G, Swanney MP, Crapo RO, Pedersen OF, Falaschetti E, Schouten JP, Jensen RL: The need to change the method for defining mild airway obstruction. Eur Respir J. 2011, 37: 720-722. 10.1183/09031936.00135110.CrossRefPubMed
8.
go back to reference Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, Yernault JC, Decramer M, Higenbottam T, Postma DS, Rees J, on behalf of the Task Force: Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J. 1995, 8: 1398-1420. 10.1183/09031936.95.08081398.CrossRefPubMed Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, Yernault JC, Decramer M, Higenbottam T, Postma DS, Rees J, on behalf of the Task Force: Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J. 1995, 8: 1398-1420. 10.1183/09031936.95.08081398.CrossRefPubMed
9.
go back to reference Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J: Interpretative strategies for lung function tests. Eur Respir J. 2005, 26: 948-968. 10.1183/09031936.05.00035205.CrossRefPubMed Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J: Interpretative strategies for lung function tests. Eur Respir J. 2005, 26: 948-968. 10.1183/09031936.05.00035205.CrossRefPubMed
10.
go back to reference MacNee W: Clinic Practice Guidelines: more of the same?. Am J Respir Crit Care Med. 2001, 184: 492-494.CrossRef MacNee W: Clinic Practice Guidelines: more of the same?. Am J Respir Crit Care Med. 2001, 184: 492-494.CrossRef
11.
go back to reference Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, UPLIFT Study Investigators: A 4-year trial of triotropium in chronic obstructive pulmonary disease. N Engl L Med. 2008, 359: 1543-54. 10.1056/NEJMoa0805800.CrossRef Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, UPLIFT Study Investigators: A 4-year trial of triotropium in chronic obstructive pulmonary disease. N Engl L Med. 2008, 359: 1543-54. 10.1056/NEJMoa0805800.CrossRef
12.
go back to reference Washko GR, Fan VS, Ramsey SD, Mohseinifar Z, Martinez F, Make BJ, Sciurba FC, Criner GJ, Minai O, Decamp MM, Reilly JJ, National Emphysema Treatment Trial Research Group: The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exarcerbations. Am J Respir Crit Care Med. 2008, 177: 164-169.CrossRefPubMed Washko GR, Fan VS, Ramsey SD, Mohseinifar Z, Martinez F, Make BJ, Sciurba FC, Criner GJ, Minai O, Decamp MM, Reilly JJ, National Emphysema Treatment Trial Research Group: The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exarcerbations. Am J Respir Crit Care Med. 2008, 177: 164-169.CrossRefPubMed
13.
go back to reference Hogg JC, Chu F, Utokaparch S, Woods R, Elliot WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Paré PD: The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004, 350: 2645-2653. 10.1056/NEJMoa032158.CrossRefPubMed Hogg JC, Chu F, Utokaparch S, Woods R, Elliot WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Paré PD: The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004, 350: 2645-2653. 10.1056/NEJMoa032158.CrossRefPubMed
14.
go back to reference Irving CG: Will the small airways rise again?. Am J Respir Crit Care Med. 2011, 184: 499-500. 10.1164/rccm.201107-1188ED.CrossRef Irving CG: Will the small airways rise again?. Am J Respir Crit Care Med. 2011, 184: 499-500. 10.1164/rccm.201107-1188ED.CrossRef
15.
go back to reference Reilly JJ, Silverman EK, Shapiro SD: COPD. Harrison's principles of internal medicine. 2008, McGrowHill, NYC, NY, 17 Reilly JJ, Silverman EK, Shapiro SD: COPD. Harrison's principles of internal medicine. 2008, McGrowHill, NYC, NY, 17
16.
go back to reference Casanova C, Cote C, De Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, Celli BR: Inspiratory-to-Total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005, 171: 591-597.CrossRefPubMed Casanova C, Cote C, De Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, Celli BR: Inspiratory-to-Total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005, 171: 591-597.CrossRefPubMed
17.
go back to reference Roussos C, Macklem PT: The respiratory muscles. N Eng J Med. 1982, 307: 786-97. 10.1056/NEJM198209233071304.CrossRef Roussos C, Macklem PT: The respiratory muscles. N Eng J Med. 1982, 307: 786-97. 10.1056/NEJM198209233071304.CrossRef
18.
go back to reference O'Donnel DE: Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006, 3: 180-184. 10.1513/pats.200508-093DO.CrossRef O'Donnel DE: Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006, 3: 180-184. 10.1513/pats.200508-093DO.CrossRef
19.
go back to reference Cooper CB: The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med. 2006, 119 (Suppl 1): 21-31.CrossRefPubMed Cooper CB: The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med. 2006, 119 (Suppl 1): 21-31.CrossRefPubMed
20.
go back to reference Barr RG, Bluemke DA, Ahmed FS, Carr JJ, Enright PL, Hoffman EA, Jiang R, Kawut SM, Kronmal RA, Lima JA, Shahar E, Smith LJ, Watson KE: Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010, 362: 217-27. 10.1056/NEJMoa0808836.CrossRefPubMedPubMedCentral Barr RG, Bluemke DA, Ahmed FS, Carr JJ, Enright PL, Hoffman EA, Jiang R, Kawut SM, Kronmal RA, Lima JA, Shahar E, Smith LJ, Watson KE: Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010, 362: 217-27. 10.1056/NEJMoa0808836.CrossRefPubMedPubMedCentral
21.
go back to reference Siafakas NM: Preventing exacerbations of COPD - Advice from Hippocrates. N Engl J Med. 2001, 356: 753-4. Siafakas NM: Preventing exacerbations of COPD - Advice from Hippocrates. N Engl J Med. 2001, 356: 753-4.
22.
go back to reference Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA, Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators: Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010, 363: 1128-1138. 10.1056/NEJMoa0909883.CrossRefPubMed Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA, Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators: Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010, 363: 1128-1138. 10.1056/NEJMoa0909883.CrossRefPubMed
23.
go back to reference Augusti A, Calverly PMA, Celli B, Coxson HO, Edwards LD, Lomas DA, MacNee W, Miller BE, Rennard S, Silverman EK, Tal-Singer R, Wouters E, Yates JC, Vestbo J, Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators: Characterization of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010, 11: 122-CrossRef Augusti A, Calverly PMA, Celli B, Coxson HO, Edwards LD, Lomas DA, MacNee W, Miller BE, Rennard S, Silverman EK, Tal-Singer R, Wouters E, Yates JC, Vestbo J, Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators: Characterization of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010, 11: 122-CrossRef
24.
go back to reference Walter RE, Wilk JB, Larson MG, Vasan RS, Keaney JF, Lipinska I, O'Connor GT, Benjamin EJ: Systemic inflammation and COPD. The Framingham Heart Study. Chest. 2008, 133: 19-25. 10.1378/chest.07-0058.CrossRefPubMed Walter RE, Wilk JB, Larson MG, Vasan RS, Keaney JF, Lipinska I, O'Connor GT, Benjamin EJ: Systemic inflammation and COPD. The Framingham Heart Study. Chest. 2008, 133: 19-25. 10.1378/chest.07-0058.CrossRefPubMed
25.
go back to reference Fabbri LM, Rabe KF: From COPD to chronic systemic inflammatory syndrome?. Lancet. 2007, 370: 797-99. 10.1016/S0140-6736(07)61383-X.CrossRefPubMed Fabbri LM, Rabe KF: From COPD to chronic systemic inflammatory syndrome?. Lancet. 2007, 370: 797-99. 10.1016/S0140-6736(07)61383-X.CrossRefPubMed
26.
go back to reference van Dijk WD, van den Bemt L, van den Haak-Rongen S, Bischoff E, van Weel C, Veen JCCM, Schermer TRJ: Multidimensional prognostic indices for use in COPD patient care. A systematic review. Respir Res. 2011 van Dijk WD, van den Bemt L, van den Haak-Rongen S, Bischoff E, van Weel C, Veen JCCM, Schermer TRJ: Multidimensional prognostic indices for use in COPD patient care. A systematic review. Respir Res. 2011
27.
go back to reference Fletcher C, Peto R, Tinker C, Speizer FE: The Natural history of chronic bronchitis and emphysema. 1976, Oxford University Press. Oxford Fletcher C, Peto R, Tinker C, Speizer FE: The Natural history of chronic bronchitis and emphysema. 1976, Oxford University Press. Oxford
29.
go back to reference Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palange P, Parr D, Pistolesi M, Rennard SI, Rutten-van Mölken MP, Stockley R, Sullivan SD, Wedzicha JA, Wouters EF, on behalf of the American Thoracic Society/European Respiratory Society Task Force on outcomes of COPD: Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008, 31: 416-468. 10.1183/09031936.00099306.CrossRefPubMed Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palange P, Parr D, Pistolesi M, Rennard SI, Rutten-van Mölken MP, Stockley R, Sullivan SD, Wedzicha JA, Wouters EF, on behalf of the American Thoracic Society/European Respiratory Society Task Force on outcomes of COPD: Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008, 31: 416-468. 10.1183/09031936.00099306.CrossRefPubMed
30.
go back to reference Augusti A, Vestbo J: Current controversies and future perspectives in COPD. AJRCCM. 2011 Augusti A, Vestbo J: Current controversies and future perspectives in COPD. AJRCCM. 2011
31.
go back to reference Netter FH: Atlas of human anatomy. Pulmonary Chronic Obstructive Disease. 1980, Ciba Collection, 4: 148-149. Netter FH: Atlas of human anatomy. Pulmonary Chronic Obstructive Disease. 1980, Ciba Collection, 4: 148-149.
32.
go back to reference Tashkin DP: Frequent exacerbation of COPD a distinct phenotypes?. N Engl J Med. 2010, 363: 1183-4. 10.1056/NEJMe1008184.CrossRefPubMed Tashkin DP: Frequent exacerbation of COPD a distinct phenotypes?. N Engl J Med. 2010, 363: 1183-4. 10.1056/NEJMe1008184.CrossRefPubMed
33.
go back to reference Parr DG: Patient phenotyping and early disease detection in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2011, 8: 338-349. 10.1513/pats.201101-014RM.CrossRefPubMed Parr DG: Patient phenotyping and early disease detection in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2011, 8: 338-349. 10.1513/pats.201101-014RM.CrossRefPubMed
34.
go back to reference Hurst JR: Exarcerbation phenotyping in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011, 184: 625-626. 10.1164/rccm.201106-1136ED.CrossRefPubMed Hurst JR: Exarcerbation phenotyping in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011, 184: 625-626. 10.1164/rccm.201106-1136ED.CrossRefPubMed
35.
go back to reference Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JAD, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, Make B, Marchetti N, Martinez FJ, Madinger NE, McEvoy C, Niewoehner DE, Porsasz J, Price CS, Reilly J, Scanlon PD, Sciurba FC, Scharf SM, Washko GR, Woodruff PG, Anthonisen NR, COPD Clinical Research Network: Azithromycin for prevention of exacerbation of COPD. N Engl J Med. 2011, 365: 389-98.CrossRef Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JAD, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, Make B, Marchetti N, Martinez FJ, Madinger NE, McEvoy C, Niewoehner DE, Porsasz J, Price CS, Reilly J, Scanlon PD, Sciurba FC, Scharf SM, Washko GR, Woodruff PG, Anthonisen NR, COPD Clinical Research Network: Azithromycin for prevention of exacerbation of COPD. N Engl J Med. 2011, 365: 389-98.CrossRef
36.
go back to reference Rupert CJ, Donaldson GC, Chavannes NH, Kida K, Dickson-Spillmann M, Harding S, Wedzicha JA, Price D, Hyland ME: Derivation and validation of Composite Index of severity in chronic obstructive pulmonary disease. The DOSE index. Am J Respir Crit Care Med. 2009, 180: 1189-95. 10.1164/rccm.200902-0271OC.CrossRef Rupert CJ, Donaldson GC, Chavannes NH, Kida K, Dickson-Spillmann M, Harding S, Wedzicha JA, Price D, Hyland ME: Derivation and validation of Composite Index of severity in chronic obstructive pulmonary disease. The DOSE index. Am J Respir Crit Care Med. 2009, 180: 1189-95. 10.1164/rccm.200902-0271OC.CrossRef
37.
go back to reference Postma DS, Calverly P: Inhaled corticosteroids in COPD: a case in favor. Eur Resp J. 2009, 34: 10-12. 10.1183/09031936.00022809.CrossRef Postma DS, Calverly P: Inhaled corticosteroids in COPD: a case in favor. Eur Resp J. 2009, 34: 10-12. 10.1183/09031936.00022809.CrossRef
38.
go back to reference Suissa S, Barnes PJ: Inhaled corticosteroids in COPD: the case against. Eur Respi J. 2009, 34: 13-16. 10.1183/09031936.00190908.CrossRef Suissa S, Barnes PJ: Inhaled corticosteroids in COPD: the case against. Eur Respi J. 2009, 34: 13-16. 10.1183/09031936.00190908.CrossRef
39.
go back to reference Lapperre TS, Snoeck-Stroband JB, Gosman MME, Jansen DF, van Schadewijk A, Thiadens HA, Vonk JM, Boezen HM, Ten Hacken NH, Sont JK, Rabe KF, Kerstjens HA, Hiemstra PS, Timens W, Postma DS, Sterk PJ, Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease Study Group: Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2009, 151: 517-27.CrossRefPubMed Lapperre TS, Snoeck-Stroband JB, Gosman MME, Jansen DF, van Schadewijk A, Thiadens HA, Vonk JM, Boezen HM, Ten Hacken NH, Sont JK, Rabe KF, Kerstjens HA, Hiemstra PS, Timens W, Postma DS, Sterk PJ, Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease Study Group: Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2009, 151: 517-27.CrossRefPubMed
40.
go back to reference Fabbri LM, Romagnoli M, Corbetta L, Casoni G, Busljetic K, Turato G, Ligabue G, Ciaccia A, Saetta M, Papi A: Differences in airway inflammation in patients with fixed obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003, 167: 418-424. 10.1164/rccm.200203-183OC.CrossRefPubMed Fabbri LM, Romagnoli M, Corbetta L, Casoni G, Busljetic K, Turato G, Ligabue G, Ciaccia A, Saetta M, Papi A: Differences in airway inflammation in patients with fixed obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003, 167: 418-424. 10.1164/rccm.200203-183OC.CrossRefPubMed
41.
go back to reference Brightling CE, McKenna S, Hargadon B, Birring S, Green R, Siva R, Berry M, Parker D, Monteiro W, Pavord ID, Bradding P: Sputum eosinophilia and short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax. 2005, 60: 193-198. 10.1136/thx.2004.032516.CrossRefPubMedPubMedCentral Brightling CE, McKenna S, Hargadon B, Birring S, Green R, Siva R, Berry M, Parker D, Monteiro W, Pavord ID, Bradding P: Sputum eosinophilia and short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax. 2005, 60: 193-198. 10.1136/thx.2004.032516.CrossRefPubMedPubMedCentral
42.
go back to reference Decreamer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP, for the UPLIFT investigators: Effect of tiotropium on outocomes in patients with moderate chronic obstructive pulmoanry disease (UPLIFT): a prespecified subgroup analysis of a randomized controlled trails. Lancet. 2009, 374: 1171-8. 10.1016/S0140-6736(09)61298-8.CrossRef Decreamer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP, for the UPLIFT investigators: Effect of tiotropium on outocomes in patients with moderate chronic obstructive pulmoanry disease (UPLIFT): a prespecified subgroup analysis of a randomized controlled trails. Lancet. 2009, 374: 1171-8. 10.1016/S0140-6736(09)61298-8.CrossRef
43.
go back to reference Celli B, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM: Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from TORCH study. Am J Respir Crit Care Med. 2008, 178: 332-338. 10.1164/rccm.200712-1869OC.CrossRefPubMed Celli B, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM: Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from TORCH study. Am J Respir Crit Care Med. 2008, 178: 332-338. 10.1164/rccm.200712-1869OC.CrossRefPubMed
44.
go back to reference Kohansal R, Martinez-Camblor P, Augusti A, Buist AS, Mannino DM, Soriano JB: The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med. 2009, 180: 3-10. 10.1164/rccm.200901-0047OC.CrossRefPubMed Kohansal R, Martinez-Camblor P, Augusti A, Buist AS, Mannino DM, Soriano JB: The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med. 2009, 180: 3-10. 10.1164/rccm.200901-0047OC.CrossRefPubMed
45.
go back to reference Renanrd SI, Vestbo J: Natural histories of chronic obstructive pulmoanry disease. Proc Am, Thorac Soc. 2008, 8: 878-883.CrossRef Renanrd SI, Vestbo J: Natural histories of chronic obstructive pulmoanry disease. Proc Am, Thorac Soc. 2008, 8: 878-883.CrossRef
Metadata
Title
E pluribus plurima: Multidimensional indices and clinical phenotypes in COPD
Authors
Andrea Rossi
Erika Zanardi
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2011
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-12-152

Other articles of this Issue 1/2011

Respiratory Research 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine